Separately, Maxim Group set a $8.00 price objective on shares of TrovaGene and gave the company a “buy” rating in a research report on Thursday, May 23rd.
Shares of NASDAQ:PAVM traded down $0.01 during trading on Friday, reaching $1.05. 296,600 shares of the company’s stock traded hands, compared to its average volume of 277,235. PAVmed has a 12 month low of $0.86 and a 12 month high of $1.70. The company’s 50 day moving average is $1.11.
PAVmed (NASDAQ:PAVM) last announced its quarterly earnings data on Tuesday, May 21st. The company reported ($0.09) earnings per share for the quarter.
In other PAVmed news, CEO Lishan Aklog acquired 30,000 shares of the stock in a transaction that occurred on Thursday, May 23rd. The stock was acquired at an average price of $1.10 per share, with a total value of $33,000.00. Following the transaction, the chief executive officer now directly owns 848,413 shares in the company, valued at $933,254.30. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 34.40% of the stock is owned by corporate insiders.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
See Also: Momentum Indicators
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.